Spots Global Cancer Trial Database for recurrent adult primary liver cancer
Every month we try and update this database with for recurrent adult primary liver cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer | NCT00274885 | Cancer | oxaliplatin management of t... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | NCT01730937 | Adult Primary H... Advanced Adult ... Recurrent Adult... | Sorafenib stereotactic bo... | 18 Years - | Radiation Therapy Oncology Group | |
| BMS-247550 in Treating Patients With Liver or Gallbladder Cancer | NCT00023946 | Adult Primary C... Adult Primary H... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Localized Extra... Localized Gallb... Localized Resec... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | ixabepilone laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) | NCT00077142 | Liver Cancer | TAC-101 | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed | NCT00006006 | Liver Cancer | recombinant int... thalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer | NCT00081094 | Liver Cancer | 18F-Fluorodeoxy... 11Carbon-Acetat... | 18 Years - | Washington University School of Medicine | |
| Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer | NCT00107536 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery | NCT00873002 | Liver Cancer | panobinostat sorafenib tosyl... | 18 Years - | Case Comprehensive Cancer Center | |
| PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer | NCT02088775 | Adult Primary H... Advanced Adult ... Metastatic Extr... Recurrent Adult... Recurrent Extra... Stage D Adult P... Unspecified Adu... | PET scan CT Scan hepatic artery ... | 18 Years - | Fox Chase Cancer Center | |
| Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer | NCT00073905 | Extrahepatic Bi... Gallbladder Can... Liver Cancer Pain | capecitabine pl... | 18 Years - 80 Years | Swiss Group for Clinical Cancer Research | |
| Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer | NCT00003427 | Anal Cancer Colorectal Canc... Esophageal Canc... Extrahepatic Bi... Gallbladder Can... Gastric Cancer Gastrointestina... Liver Cancer Pancreatic Canc... Small Intestine... | irinotecan hydr... oxaliplatin | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer | NCT00009893 | Extrahepatic Bi... Gallbladder Can... Liver Cancer | fluorouracil gemcitabine hyd... leucovorin calc... | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery | NCT00039078 | Liver Cancer | yttrium Y 90 gl... | 18 Years - 120 Years | University of Pittsburgh | |
| Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer | NCT01009801 | Liver Cancer | doxorubicin-elu... everolimus placebo | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery | NCT02072356 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | yttrium Y 90 gl... laboratory biom... TheraSphere | 8 Years - | Ohio State University Comprehensive Cancer Center | |
| Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder | NCT00085410 | Adenocarcinoma ... Adenocarcinoma ... Advanced Adult ... Gastrointestina... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | bortezomib | 18 Years - | National Cancer Institute (NCI) | |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00082823 | Cancer | ziv-aflibercept | 18 Years - 120 Years | Regeneron Pharmaceuticals | |
| Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum | NCT00005860 | Cancer | floxuridine leucovorin calc... oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer | NCT00003439 | Cancer | recombinant int... | 18 Years - | National Cancer Institute (NCI) | |
| Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers | NCT01229111 | Adult Primary C... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Localized Unres... Periampullary A... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | cediranib malea... oxaliplatin leucovorin calc... fluorouracil | 18 Years - | National Cancer Institute (NCI) | |
| Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity | NCT00003548 | Cancer | aminocamptothec... | 18 Years - | NYU Langone Health | |
| Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00514228 | Liver Cancer | sunitinib malat... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors | NCT00093444 | Liver Cancer Metastatic Canc... | lyso-thermosens... radiofrequency ... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer | NCT00604721 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | selumetinib pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | NCT00031681 | Advanced Adult ... Carcinoma of th... Estrogen Recept... Extensive Stage... Gastrointestina... HER2-negative B... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Progesterone Re... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Borde... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Endom... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Border... Stage IV Breast... Stage IV Colon ... Stage IV Endome... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Stage IVA Cervi... Stage IVB Cervi... Triple-negative... Unresectable Ex... Unresectable Ga... Unspecified Adu... Untreated Metas... | 7-hydroxystauro... irinotecan hydr... diagnostic labo... | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00335829 | Liver Cancer | bevacizumab chemotherapy embolization th... hepatic artery ... | 18 Years - 120 Years | Yale University | |
| Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00335829 | Liver Cancer | bevacizumab chemotherapy embolization th... hepatic artery ... | 18 Years - 120 Years | Yale University | |
| Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant | NCT01194206 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | stereotactic bo... | 18 Years - 70 Years | Case Comprehensive Cancer Center | |
| Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer | NCT00253708 | Cancer | management of t... massage therapy pain therapy psychosocial as... quality-of-life... | 18 Years - 120 Years | Beth Israel Deaconess Medical Center | |
| Irinotecan and Capecitabine in Treating Patients With Solid Tumors | NCT00003867 | Cancer | capecitabine irinotecan hydr... | 18 Years - 120 Years | Montefiore Medical Center | |
| Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer | NCT00739167 | Liver Cancer Metastatic Canc... | 18 Years - | Northwestern University | ||
| Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors | NCT00002608 | Adrenocortical ... Brain and Centr... Head and Neck C... Liver Cancer Malignant Mesot... Pheochromocytom... Sarcoma | cisplatin doxorubicin hyd... tamoxifen citra... conventional su... radiation thera... | - 65 Years | National Cancer Institute (NCI) | |
| Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer | NCT00607828 | Liver Cancer | stereotactic bo... | 19 Years - 120 Years | University of Nebraska | |
| Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis | NCT01079767 | Liver Cancer | temsirolimus | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| IMC-A12 in Treating Patients With Advanced Liver Cancer | NCT00639509 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | cixutumumab computed tomogr... contrast-enhanc... | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer | NCT00881751 | Liver Cancer | bevacizumab erlotinib hydro... sorafenib tosyl... | 18 Years - 116 Years | Medical University of South Carolina | |
| Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer | NCT00436410 | Adrenocortical ... Breast Cancer Colorectal Canc... Gastrointestina... Kidney Cancer Liver Cancer Melanoma (Skin) Ovarian Cancer Pancreatic Canc... Sarcoma | colloidal gold-... electron micros... pharmacological... conventional su... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | NCT00101036 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer | NCT00486356 | Extrahepatic Bi... Gallbladder Can... Gastric Cancer Liver Cancer Unspecified Adu... | capecitabine carboplatin epirubicin hydr... microarray anal... polymorphism an... pharmacological... | 18 Years - 120 Years | University of Nebraska | |
| Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer | NCT01624285 | Adult Primary H... Localized Resec... Localized Unres... Recurrent Adult... | sorafenib tosyl... placebo laboratory biom... | 19 Years - | Jonsson Comprehensive Cancer Center | |
| Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) | NCT00071994 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | gefitinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction | NCT00047346 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | erlotinib hydro... pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer | NCT00027534 | Breast Cancer Colorectal Canc... Gallbladder Can... Gastric Cancer Head and Neck C... Liver Cancer Ovarian Cancer Pancreatic Canc... Testicular Germ... | TRICOM-CEA(6D) | 18 Years - | Duke University | |
| Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors | NCT00093444 | Liver Cancer Metastatic Canc... | lyso-thermosens... radiofrequency ... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| BMS-247550 in Treating Patients With Liver or Gallbladder Cancer | NCT00023946 | Adult Primary C... Adult Primary H... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Localized Extra... Localized Gallb... Localized Resec... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | ixabepilone laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer | NCT00087191 | Advanced Adult ... Carcinoma of th... Fallopian Tube ... Gastrointestina... Localized Extra... Localized Gallb... Localized Gastr... Localized Resec... Localized Unres... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Primary Periton... Recurrent Adult... Recurrent Adult... Recurrent Colon... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Recurrent Small... Recurrent Uteri... Regional Gastro... Small Intestine... Small Intestine... Small Intestine... Stage 0 Non-sma... Stage I Adult S... Stage I Colon C... Stage I Gastric... Stage I Non-sma... Stage I Ovarian... Stage I Ovarian... Stage I Pancrea... Stage I Rectal ... Stage I Uterine... Stage II Adult ... Stage II Colon ... Stage II Gastri... Stage II Non-sm... Stage II Ovaria... Stage II Ovaria... Stage II Pancre... Stage II Rectal... Stage II Uterin... Stage III Adult... Stage III Colon... Stage III Gastr... Stage III Ovari... Stage III Ovari... Stage III Pancr... Stage III Recta... Stage III Uteri... Stage IIIA Non-... Stage IIIB Non-... Stage IV Adult ... Stage IV Colon ... Stage IV Gastri... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Rectal... Stage IV Uterin... Unresectable Ex... Unresectable Ga... | EF5 motexafin lutet... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer | NCT00009893 | Extrahepatic Bi... Gallbladder Can... Liver Cancer | fluorouracil gemcitabine hyd... leucovorin calc... | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00335829 | Liver Cancer | bevacizumab chemotherapy embolization th... hepatic artery ... | 18 Years - 120 Years | Yale University | |
| Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed | NCT00006006 | Liver Cancer | recombinant int... thalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer | NCT00739167 | Liver Cancer Metastatic Canc... | 18 Years - | Northwestern University | ||
| Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer | NCT00867321 | Liver Cancer | bevacizumab sorafenib tosyl... | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant | NCT00844168 | Adult Primary H... Advanced Adult ... Localized Resec... Localized Unres... Recurrent Adult... | sorafenib tosyl... laboratory biom... | 18 Years - | University of Washington | |
| Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer | NCT00033462 | Adult Primary C... Adult Primary H... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | erlotinib hydro... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00514228 | Liver Cancer | sunitinib malat... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer | NCT02088775 | Adult Primary H... Advanced Adult ... Metastatic Extr... Recurrent Adult... Recurrent Extra... Stage D Adult P... Unspecified Adu... | PET scan CT Scan hepatic artery ... | 18 Years - | Fox Chase Cancer Center | |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | NCT00397384 | Adenocarcinoma ... Adenocarcinoma ... Advanced Adult ... Carcinoma of th... Gastrointestina... Metastatic Gast... Metastatic Squa... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Colon... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Pancr... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Colon ... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Pancre... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Tongue Cancer Unresectable Ex... Unresectable Ga... | cetuximab erlotinib hydro... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer | NCT00073905 | Extrahepatic Bi... Gallbladder Can... Liver Cancer Pain | capecitabine pl... | 18 Years - 80 Years | Swiss Group for Clinical Cancer Research | |
| AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer | NCT00427973 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | cediranib malea... laboratory biom... computed tomogr... dynamic contras... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | NCT00019474 | Extrahepatic Bi... Gastric Cancer Gastrointestina... Liver Cancer Pancreatic Canc... Small Intestine... | filgrastim recombinant int... fluorouracil hydroxyurea | 18 Years - 120 Years | Montefiore Medical Center | |
| Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery | NCT00049322 | Liver Cancer | bevacizumab | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Irinotecan and Capecitabine in Treating Patients With Solid Tumors | NCT00003867 | Cancer | capecitabine irinotecan hydr... | 18 Years - 120 Years | Montefiore Medical Center | |
| Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer | NCT00257426 | Liver Cancer | octreotide acet... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00589030 | Liver Cancer | brachytherapy yttrium Y 90 gl... | 18 Years - | City of Hope Medical Center | |
| Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery | NCT00109954 | Liver Cancer | cisplatin brachytherapy yttrium Y 90 gl... | 18 Years - 120 Years | University of Pittsburgh | |
| Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer | NCT00003296 | Extrahepatic Bi... Gallbladder Can... Liver Cancer | filgrastim pegylated lipos... | 18 Years - | National Cancer Institute (NCI) | |
| Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen | NCT00016380 | Cancer | dexamethasone ondansetron quality-of-life... | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery | NCT01497444 | Kidney Cancer Liver Cancer | hypoxia-activat... sorafenib tosyl... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis | NCT01079767 | Liver Cancer | temsirolimus | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors | NCT00019331 | Colorectal Canc... Endometrial Can... Head and Neck C... Liver Cancer Lung Cancer Melanoma (Skin) Pancreatic Canc... Testicular Germ... Unspecified Adu... | aldesleukin ras peptide can... sargramostim DetoxPC | 18 Years - | National Cancer Institute (NCI) | |
| Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00589030 | Liver Cancer | brachytherapy yttrium Y 90 gl... | 18 Years - | City of Hope Medical Center | |
| Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery | NCT00049322 | Liver Cancer | bevacizumab | 18 Years - | Jonsson Comprehensive Cancer Center | |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | NCT00031681 | Advanced Adult ... Carcinoma of th... Estrogen Recept... Extensive Stage... Gastrointestina... HER2-negative B... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Progesterone Re... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Borde... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Endom... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Border... Stage IV Breast... Stage IV Colon ... Stage IV Endome... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Stage IVA Cervi... Stage IVB Cervi... Triple-negative... Unresectable Ex... Unresectable Ga... Unspecified Adu... Untreated Metas... | 7-hydroxystauro... irinotecan hydr... diagnostic labo... | 18 Years - | National Cancer Institute (NCI) | |
| Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery | NCT01859182 | Adenocarcinoma ... Adenocarcinoma ... Adult Primary C... Advanced Adult ... Cholangiocarcin... Localized Unres... Metastatic Extr... Recurrent Adult... Recurrent Extra... Stage II Gallbl... Stage IIIA Gall... Stage IIIB Gall... Stage IVA Gallb... Stage IVB Gallb... Unresectable Ex... | selumetinib Akt inhibitor M... laboratory biom... pharmacogenomic... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00524316 | Liver Cancer | doxorubicin hyd... sunitinib malat... laboratory biom... hepatic artery ... quality-of-life... | 18 Years - 120 Years | Roswell Park Cancer Institute | |
| Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer | NCT00003557 | Extrahepatic Bi... Gallbladder Can... Liver Cancer | dolastatin 10 | 18 Years - | University of Chicago | |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00083213 | Cancer | ziv-aflibercept | 18 Years - 120 Years | Regeneron Pharmaceuticals | |
| Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00524316 | Liver Cancer | doxorubicin hyd... sunitinib malat... laboratory biom... hepatic artery ... quality-of-life... | 18 Years - 120 Years | Roswell Park Cancer Institute | |
| Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | NCT00101036 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
